New Weight Loss Pill Could Compete with Popular Injection

Pfizer's new pill, danuglipron, produced weight loss comparable to Novo Nordisk's injected Ozempic in trials.
Novo Nordisk's trials of an oral version of its drug semaglutide resulted in significant weight loss.
Novo Nordisk and Pfizer both plan to seek approval for their weight loss pills.
If approved, the new pills could transform the growing weight loss drug market.
The popularity of injected weight loss drugs like Ozempic highlights the demand for simple, effective obesity treatments.